The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:1302-1304 March 20, 2008 Number 12
NextNext

Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Sambrook, P. N.
-Related Article
by Saag, K. G.
To the Editor: The trial reported by Saag and colleagues (Nov. 15 issue)1 compared teriparatide (Forteo) with alendronate (Fosamax) in patients with glucocorticoid-induced osteoporosis. The study enrolled patients who had received long-term treatment with glucocorticoids, defined as a mean daily dose of 5 mg or more of prednisone or its equivalent for 3 or more consecutive months preceding the screening visit.

This exposure constitutes a reasonable risk.1 However, we believe that it is not sufficient to make a proper diagnosis of glucocorticoid-induced osteoporosis in the absence of an objective assessment of the bone mineral density before the initiation of treatment . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.